HTG Molecular Diagnostics Inc Shares Close the Week 20.4% Lower - Weekly Wrap
The company saw its shares close the week 20.4% lower than last week, with trading volume lower than its 30 day average.
Jan 12, 2022 by Kwhen Finance Editors
HTG Molecular Diagnostics Inc (HTGM) shares closed this week 20.4% lower than it did at the end of last week. The stock is currently down 21.6% year-to-date, down 29.9% over the past 12 months, and down 86.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%.
Trading Activity
- Shares traded as high as $5.35 and as low as $4.17 this week.
- Shares closed 46.5% below its 52-week high and 33.2% above its 52-week low.
- Trading volume this week was 20.3% lower than the 10-day average and 59.2% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.0.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
- The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| HTG Molecular Diagnostics Inc | -3.8 | -21.6 | -29.9 | ||
| Dow Jones Industrial Average | 0.5 | -0.7 | 18.0 | -2.4 | 22.8 |
| S&P 500 Index | 0.9 | -2.0 | 23.7 | -3.1 | 28.0 |
| Health Care | 0.8 | -4.3 | 14.2 | -4.7 | 22.4 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 127.3%
- The company's stock price performance over the past 12 months beats the peer average by -33.6%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| HTG Molecular Diagnostics Inc | HTGM | 0 | -21.6 | -29.9 | ||
| Peer Avg | N/A | -3.1 | -9.5 | -45.0 | ||
| Lexicon Pharmaceuticals Inc | LXRX | -8.1 | -6.6 | -5.6 | ||
| Affimed N.V. | AFMD | 0 | -14.5 | -24.8 | ||
| Radius Health Inc. | RDUS | -4.2 | -3.5 | -70.4 | ||
| Calithera Biosciences Inc | CALA | 0 | -13.4 | -79.1 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: